SCHEMBL1521565

SCHEMBL1521565

CCN1C(=O)N(c2cc(NC(=O)Nc3cccc(C(F)(F)F)c3)c(F)cc2C)Cc2cnc(NC)cc21

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 14/20 0.46
MAPK14 Q16539 12/20 0.46
TNNI3K Q59H18 11/20 0.46
BRAF P15056 7/20 0.46
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
RIPK2 O43353 1/20 0.43
RAF1 P04049 1/20 0.42
MAPK3 P27361 1/20 0.42
TNK2 Q07912 3/20 0.42
MAP4K2 Q12851 3/20 0.42
ABL1 P00519 2/20 0.42
LCK P06239 2/20 0.42
FES P07332 1/20 0.42
RET P07949 1/20 0.42
PDGFRB P09619 1/20 0.42
KIT P10721 1/20 0.42
FGFR1 P11362 1/20 0.42
SRC P12931 1/20 0.42
PDGFRA P16234 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1521686 0.93 KDR (0.45) KDRMAPK14TNNI3KBRAFMEN1
SCHEMBL1521902 0.92 KDR (0.45) KDRMAPK14TNNI3KBRAFMEN1
SCHEMBL1521657 0.84 TRPV1 (0.42) KDRBRAFRAF1KITFGFR1
SCHEMBL1521521 0.82 KDR (0.47) KDRMAPK14TNNI3KBRAFMEN1
SCHEMBL1521766 0.81 TNK2 (0.42) KDRMAPK14BRAFMAPK3TNK2
SCHEMBL1521817 0.81 BRAF (0.40) KDRMAPK14BRAFMEN1KMT2A
SCHEMBL1521745 0.81 TNK2 (0.59) KDRMAPK3TNK2MAP4K2ABL1
SCHEMBL1521678 0.81 KDR (0.40) KDRMAPK14TNNI3KBRAFRAF1
SCHEMBL1521993 0.80 KDR (0.39) KDRMAPK14TNNI3KBRAFRIPK2
SCHEMBL1521431 0.80 BRAF (0.52) KDRMAPK14BRAFRAF1FGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases FLYNN DANIEL L 2011-05-19 US claimed
US-7897762-B2 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2011-03-01 US claimed
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases FLYNN DANIEL L 2011-05-19 US disclosed
US-7897762-B2 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2011-03-01 US disclosed
EP-2063896-A2 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES Deciphera Pharmaceuticals, LLC. (US) 2009-06-03 EP disclosed
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2009-04-16 US disclosed
WO-2008033999-A2 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS, LLC (US) 2008-03-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases BRAF, PRKDC, RAF1 KDR 500/4885MAPK14 240/4885TNNI3K 143/4885
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases BRAF, PRKDC, RAF1 KDR 500/4885MAPK14 240/4885TNNI3K 143/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.